Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

News Daily News

Valve Thrombosis in TTVR Not Uncommon: Meta-analysis

June 17, 2025

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

June 06, 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

News Conference News CRT 2025

Need for Rethink of Discharge Medications After LAA Closure? EMERGE

March 12, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

News Daily News

More Excess Bleeding Seen With Rivaroxaban vs Other NOACs and Aspirin

February 14, 2025

Aspirin Use for Primary Prevention Declining in US: NHANES

News Daily News

Aspirin Use for Primary Prevention Declining in US: NHANES

Michael O'Riordan

January 24, 2025

Intra-arterial Lytics Don’t Help After Stroke Thrombectomy, but Questions Persist

News Daily News

Intra-arterial Lytics Don’t Help After Stroke Thrombectomy, but Questions Persist

January 15, 2025

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.